Epigenetic transgenerational actions of vinclozolin on the development of disease and cancer

Critical Reviews in Oncogenesis

Volumn 13, Issue 1, 2007, Pages 75-82

  Skinner, Michael K ^a   Anway, Matthew D ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Adult onset disease; DNA methylation; Epigenetics; Gonadal development; Transgenerational

Indexed keywords

VINCLOZOLIN;

DISEASE COURSE; DNA SEQUENCE; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; EPIGENETICS; GENE MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SEX DETERMINATION;

EID: 34548472614     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v13.i1.30     Document Type: Review

References (29)

1. Anway MD, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors. Endocrinology. 2006;147(6 Suppl):S43-9.
2. Newbold RR, Hanson RB, Jefferson WN, Bullock BC, Haseman J, McLachlan JA. Increased tumors but uncompromised fertility in the female descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis. 1998;19(9):1655-63.
3. Zambrano E, Martinez-Samayoa PM, Bautista CJ, Deas M, Guillen L, Rodriguez-Gonzalez GL, Guzman C, Larrea F, Nathanielsz PW. Sex differences in transgenerational alterations of growth and metabolism in progeny (F2) of female offspring (F1) of rats fed a low protein diet during pregnancy and lactation. J Physiol. 2005;566(Pt 1):225-36.
4. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005;308(5727):1466-9.
5. Anway MD, Memon MA, Uzumcu M, Skinner MK. Transgenerational effect of the endocrine disruptor vinclozolin on male spermatogenesis. J Androl. 2006;27(6):868-79.
6. Anway MD, Leathers C, Skinner MK. Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. Endocrinology. 2006;147(12):5515-23.
7. Kelce WR, Monosson E, Gamcsik MP, Laws SC, Gray LE, Jr. Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is mediated by antiandrogenic metabolites. Toxicol Appl Pharmacol. 1994;126(2):276-85.
8. Cupp AS, Uzumcu M, Suzuki H, Dirks K, Phillips B, Skinner MK. Effect of transient embryonic in vivo exposure to the endocrine disruptor methoxychlor on embryonic and postnatal testis development. J Androl. 2003;24(5):736-45.
9. Gluckman PD, Hanson MA. Developmental origins of disease paradigm: a mechanistic and evolutionary perspective. Pediatr Res. 2004;56(3):311-7.
10. Heindel JJ. The fetal basis of adult disease: Role of environmental exposures - introduction. Birth Defects Res A Clin Mol Teratol. 2005;73(3):131-2.
11. Barber R, Plumb MA, Boulton E, Roux I, Dubrova YE. Elevated mutation rates in the germ line of first- and second-generation offspring of irradiated male mice. Proc Natl Acad Sci U S A. 2002;99(10):6877-82.
12. Yamazaki Y, Mann MR, Lee SS, Marh J, McCarrey JR, Yanagimachi R, Bartolomei MS. Reprogramming of primordial germ cells begins before migration into the genital ridge, making these cells inadequate donors for reproductive cloning. Proc Natl Acad Sci U S A. 2003;100(21):12207-12.
13. Chang HS, Anway MD, Rekow SS, Skinner MK. Transgenerational epigenetic imprinting of the male germline by endocrine disruptor exposure during gonadal sex determination. Endocrinology. 2006;147(12):5524-41.
14. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 2006;66(11):5624-32.
15. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol. 2007;177(3):822-31.
16. Manoharan M, Ramachandran K, Soloway MS, Singal R. Epigenetic targets in the diagnosis and treatment of prostate cancer. Int Braz J Urol. 2007;33(1):11-8.
17. Schulz WA, Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med. 2006;10(1):100-25.
18. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol. 2004;14(6):427-32.
19. Jass JR. Heredity and DNA methylation in colorectal cancer. Gut. 2007;56(1):154-5.
20. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006;3(12):e486.
21. Tsuchiya T, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene. 2000;19(32):3642-6.
22. Herranz M, Esteller M. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Methods Mol Biol. 2007;361:25-62.
23. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6(8):597-610.
24. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome - components and functional correlates. Genes Dev. 2006;20(23):3215-31.
25. Dolinoy DC, Weidman JR, Jirtle RL. Epigenetic gene regulation: Linking early developmental environment to adult disease. Reprod Toxicol. 2007;23(3):297-307.
26. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 2007;22(2):91-103.
27. van Vliet J, Oates NA, Whitelaw E. Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci. 2007; 64:1531-8.
28. Weidman JR, Dolinoy DC, Murphy SK, Jirtle RL. Cancer susceptibility: epigenetic manifestation of environmental exposures. Cancer. J 2007;13(1):9-16.
29. Dolinoy DC, Das R, Weidman JR, Jirtle RL. Metastable epialleles, imprinting, and the fetal origins of adult diseases. Pediatr Res. 2007;61(5 Pt 2):30R-7R.